| Objective response (%) | Median of survival (month) |
Pemetrexed | 27% | 9.6% |
Docetaxel | 13% | 9% |
Paclitaxel | 10% | 7% |
Ifosfamide | 5% - 20% | 5.5% |
Gemcitabine | 11% - 23% | 5.8% |
Vinfluvine | 9% | 6.9% |